• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Zyflo (zileuton) tablets and Zyflo CR (zileuton) extended-release tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- August 2009


Summary View



Neuropsychiatric Events
  • Neuropsychiatric events have been reported in adult and adolescent patients taking zileuton, the active ingredient in Zyflo and zileuton extended-release tablets. Post-marketing reports with zileuton include sleep disorders and behavior changes. The clinical details of some post-marketing reports involving Zyflo appear consistent with a drug induced effect. Patients and prescribers should be alert for neuropsychiatric events. Patients should be instructed to notify their prescriber if these changes occur. Prescribers should carefully evaluate the risks and benefits of continuing treatment with Zyflo if such events occur.
Information for Patients
  • Patients should be instructed to notify their healthcare provider if neuropsychiatric events occur while using Zyflo.


Post-Marketing Experience
  • Cases of sleep disorders and behavior changes have also been reported